INTENT Biologics, a clinical-stage biotechnology company developing first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the ...
INTENT Biologics, a clinical-stage biotechnology company developing first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the ...
BioLab Holdings, Inc. is proud to share its continued expansion and commitment to creating jobs and improving economic impact ...
Challenges remain, like regulatory hurdles and funding, but our team's grit and your support as shareholders make me ...
New procedural codes establish standardized pathway for clinical use of autologous heterogeneous skin construct across care ...
Data is from comprehensive review of hospital charges and all-payer claims over five years - - Preventable complications such as amputation and ...
FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development ...
At the Mayo Clinic, Dr. Guifang Zhao is leading a new generation of regenerative medicine therapies that combine the ...
Xtant Medical had a busy 2025 with new product launches and sales. Six headlines to know: 1. Xtant Medical launched OsteoFactorPro, a naturally derived, growth factor-rich formulation for spine and ...
Detailed price information for Fibrobiologics Inc (FBLG-Q) from The Globe and Mail including charting and trades.
"After a review of BIASURGE®, Vizient’s client-led council agreed this technology offers a unique benefit over other products ...
FibroBiologics submits IND application with US FDA to initiate clinical trials of CYPS317 in psoriasis patients: Houston Saturday, January 3, 2026, 11:00 Hrs [IST] FibroBiologics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback